Alternative Breast Cancer Treatment at CMN Hospital
Dr. Edgar Payán treats women with all types and subtypes of breast cancer at CMN Hospital (Centro Médico del Noroeste), including hormone-positive, HER2-positive, triple-positive, triple-negative, recurrent, metastatic, and advanced breast cancer.
Every woman who comes to CMN has her own diagnosis, pathology, receptor status, medical history, previous treatments, present health condition, and individual needs. Dr. Payán reviews the complete medical picture before developing her treatment plan within CMN Hospital’s 28-day inpatient Advanced Cancer Treatment Program.
Many women find Dr. Payán after being told there is nothing more that can be done. At CMN Hospital, they are given the opportunity to have their case carefully reviewed again and to learn what additional treatment possibilities may still be available, including weekly dendritic cell therapy and, for eligible patients, bone marrow stem cell therapy using their own healthy stem cells.
Dr. Payán’s approach is centered on treating the individual woman, strengthening her body and immune system, supporting valuable immune cells including Natural Killer (NK) cells, and combining therapies according to what he determines is medically appropriate for her.
Treatment is provided inside CMN Hospital (Centro Médico del Noroeste), a fully licensed, full-service hospital in San Luis Río Colorado, Sonora, Mexico. Patients remain admitted throughout the 28-day program with 24-hour physician oversight, nursing care, laboratory monitoring, nutritional care, and continuous inpatient medical supervision.
For women who believed they had reached the end of their treatment options, CMN Hospital offers something deeply important: another medical evaluation, additional treatment possibilities, and renewed hope.
Alternative Breast Cancer Treatment Advanced inpatient care at CMN Hospital.
Treatment is provided within CMN Hospital, a licensed full-service general hospital where physician evaluations, therapies, laboratory services, meals, and daily care are coordinated in one inpatient setting.CMN Hospital provides advanced inpatient care for women with breast cancer through Dr. Edgar Payán’s 28-day Advanced Cancer Treatment program. Each patient is evaluated individually based on diagnosis, pathology, receptor status, imaging, laboratory findings, previous treatments, current condition, and overall health.
Understanding Breast Cancer
Breast cancer develops when abnormal cells in the breast grow in an uncontrolled way. It may begin in the milk ducts, lobules, or other breast tissue and can sometimes spread to lymph nodes, bones, liver, lungs, brain, or other areas of the body. Breast cancer is not one single disease. Tumors may differ by location, stage, hormone receptor status, HER2 status, grade, genetic features, prior treatment response, and whether the cancer is newly diagnosed, recurrent, or metastatic.
Because breast cancer can behave differently from one patient to another, treatment discussions should be based on a careful review of medical records, pathology, imaging, receptor testing, previous treatments, and the patient’s overall medical condition.
Types of Breast Cancer
Breast cancer may be described by where it begins, whether it has spread, and the biologic features found on pathology testing.
Invasive Ductal Carcinoma
The most common type of invasive breast cancer, beginning in the milk ducts and spreading into nearby breast tissue.
Invasive Lobular Carcinoma
A type of breast cancer that begins in the lobules and may be more difficult to detect on routine imaging.
DCIS
Ductal carcinoma in situ is a non-invasive breast cancer confined to the milk ducts.
LCIS
Lobular carcinoma in situ is not invasive cancer, but it may indicate an increased risk of developing breast cancer.
Hormone Receptor and HER2 Status
Breast cancer is also classified by hormone receptor and HER2 testing. These results help physicians understand the biology of the tumor and are important when reviewing conventional treatment options.
ER+/PR+, HER2-Negative
Hormone receptor-positive breast cancer may respond to treatments that block estrogen or progesterone activity.
ER+/PR+, HER2-Positive
This subtype is both hormone receptor-positive and HER2-positive, which may influence conventional treatment planning.
HER2-Positive, HR-Negative
This breast cancer is HER2-positive without estrogen or progesterone receptor involvement.
Triple-Negative
Triple-negative breast cancer does not express estrogen receptors, progesterone receptors, or HER2.
Triple-Positive
Triple-positive breast cancer is positive for estrogen receptors, progesterone receptors, and HER2.
Recurrent or Metastatic
Breast cancer may return after treatment or spread to distant areas of the body, requiring careful review of prior care and current findings.
Signs and Symptoms
- A lump or thickened area in the breast or underarm
- Changes in breast size, shape, or contour
- Skin dimpling, redness, scaling, or thickening
- Nipple inversion or nipple changes
- Nipple discharge, including bloody discharge
- Breast swelling, tenderness, or pain
- Enlarged lymph nodes near the breast or underarm
How Breast Cancer Is Diagnosed
Diagnosis and treatment planning may involve several tests to confirm the breast cancer type, stage, receptor status, and extent of disease.
- Mammography
- Breast ultrasound
- Breast MRI
- Core needle biopsy or surgical biopsy
- Pathology review
- Estrogen receptor testing
- Progesterone receptor testing
- HER2 testing
- Ki-67 or tumor proliferation testing when indicated
- Genetic testing, including BRCA1 and BRCA2 when appropriate
- CT, PET, bone scan, or other imaging when metastatic disease is suspected
Breast Cancer Stages
Stage 0
Non-invasive breast cancer, such as DCIS, confined to the milk ducts.
Stage I
Early breast cancer that is small and may or may not involve nearby lymph nodes.
Stage II
Breast cancer that may be larger or involve nearby lymph nodes.
Stage III
Locally advanced breast cancer involving more extensive lymph node or nearby tissue involvement.
Stage IV
Metastatic breast cancer that has spread to distant areas of the body.
Conventional Treatment Options
Conventional treatment recommendations vary based on cancer type, stage, receptor status, prior treatments, genetic findings, and the patient’s overall health.
- Lumpectomy or breast-conserving surgery
- Mastectomy
- Sentinel lymph node biopsy
- Axillary lymph node dissection
- Chemotherapy
- Radiation therapy
- Hormone therapy
- HER2-targeted therapy
- Immunotherapy for selected patients
- Targeted therapy based on tumor features
- Breast reconstruction
- Clinical trials when appropriate
Advanced and Recurrent Breast Cancer
Many women who contact CMN Hospital have already received surgery, chemotherapy, radiation therapy, hormone therapy, HER2-targeted therapy, immunotherapy, or other treatments before seeking additional options. Others may be living with recurrent, persistent, locally advanced, or metastatic breast cancer.
Because breast cancer can change over time and may respond differently after prior treatment, Dr. Payán reviews each patient’s pathology, receptor status, imaging, laboratory findings, treatment history, current condition, and overall health before discussing whether CMN Hospital’s program may be appropriate.
Individualized Physician Review
At CMN Hospital, every patient is evaluated individually. Dr. Edgar Payán, General Hospital Director and Medical Director of CMN Hospital, personally reviews each patient’s medical records, pathology reports, receptor testing, imaging studies, laboratory findings, previous treatments, current health status, and other relevant clinical information.
Following this comprehensive review, Dr. Payán meets personally with each patient during a consultation to discuss the findings, answer questions, determine whether CMN Hospital’s 28-day inpatient Advanced Cancer Treatment program may be appropriate, and explain the treatment options available based on the patient’s individual medical evaluation.
Why Women Choose CMN Hospital
Women who come to CMN Hospital for breast cancer treatment are often looking for a more organized and comprehensive approach to their care. Many arrive physically exhausted, emotionally overwhelmed, and tired of managing appointments, treatment decisions, travel, and uncertainty while carrying the weight of a breast cancer diagnosis.
Inside the 28-day inpatient program, care is brought together within one hospital environment. Therapies, laboratory services, meals, physician evaluations, and daily care are coordinated around the patient while she remains within the comfort and privacy of her suite throughout most of her stay.
If a patient proceeds with treatment, Dr. Payán oversees her care throughout the inpatient stay and continues to personally monitor her progress through scheduled monthly Zoom follow-up appointments after discharge.